Ramp Up Your AAV Productivity With Novel Engineered Plasmids And Optimized HEK293 Cell Line

Adeno-associated virus (AAV) is a popular choice as a viral vector for gene therapy due to its safety profile and effectiveness at delivering DNA to various human tissues. Strong growth in the recombinant AVV (rAAV)-based gene therapy sector is creating a need for dramatically increased production of rAAV vectors. As physically increasing manufacturing capacity is neither sufficient nor cost-effective, boosting the productivity of existing AAV production processes becomes essential.

Having previously developed a high-productivity cell line for production of rAAV via triple transient transfection in suspension cell culture, Lonza has further improved its platform process with the creation of engineered plasmids that afford significantly higher titers and productivity levels compared to standard systems.